Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Danaher Corp., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).


A consistent downward trend is observed across all three investment activity ratios – Net Fixed Asset Turnover, Total Asset Turnover, and Equity Turnover – over the analyzed period spanning from April 2022 to December 2025. The declines, while generally gradual, suggest a decreasing efficiency in utilizing assets to generate revenue.

Net Fixed Asset Turnover
This ratio exhibits a steady decline from 7.94 in April 2022 to 4.44 in December 2025. The rate of decrease appears to accelerate after September 2023, indicating a potentially more significant reduction in sales generated per dollar of net fixed assets in the later part of the period. The ratio stabilizes somewhat between September 2025 and December 2025.
Total Asset Turnover
Starting at 0.36 in April 2022, Total Asset Turnover decreases to 0.29 by December 2025. The decline is relatively consistent throughout the period, with a slight moderation in the rate of decrease between June 2024 and December 2025. This suggests a diminishing ability to generate sales from the company’s total asset base.
Equity Turnover
Equity Turnover demonstrates a similar downward trajectory, moving from 0.65 in April 2022 to 0.47 in December 2025. The rate of decline is relatively stable, although a slight increase is observed between March 2024 and September 2025 before resuming the downward trend. This indicates a decreasing efficiency in generating sales relative to shareholder equity.

The concurrent declines in all three ratios suggest a systemic shift in the company’s operational efficiency. Further investigation is warranted to determine the underlying causes, which could include factors such as changes in sales strategy, increased asset intensity, or shifts in industry dynamics. The stabilization observed in the most recent periods for some ratios may indicate a potential leveling off of these trends, but continued monitoring is crucial.


Net Fixed Asset Turnover

Danaher Corp., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Sales
Property, plant and equipment, net of accumulated depreciation
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Net fixed asset turnover = (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025) ÷ Property, plant and equipment, net of accumulated depreciation
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The net fixed asset turnover ratio demonstrates a consistent downward trend over the analyzed period, spanning from April 1, 2022, to December 31, 2025. Initially, the ratio exhibited values in the high 7s and low 8s, but progressively declined to the mid-4s by the end of the observation window.

Initial Period (Apr 1, 2022 – Sep 30, 2022)
The ratio began at 7.94 and peaked at 8.40 during this timeframe. This suggests a relatively efficient utilization of fixed assets to generate sales. However, even within this initial period, a slight fluctuation is observable.
Transitional Phase (Dec 31, 2022 – Jun 30, 2023)
A noticeable decline commenced in the final quarter of 2022, falling to 7.96, and continued through the first half of 2023, reaching 6.68. This indicates a weakening relationship between sales and net fixed assets, potentially due to increased investment in fixed assets without a corresponding increase in sales, or a decrease in sales.
Continued Decline (Sep 29, 2023 – Dec 31, 2025)
The downward trajectory persisted, with the ratio decreasing from 5.25 to 4.44 over the final two years of the period. The rate of decline appears to be moderating slightly towards the end of the period, but the overall trend remains firmly negative. The ratio stabilizes in the 4.4-4.7 range during this period.
Sales and Fixed Asset Relationship
While sales experienced fluctuations throughout the period, the decline in the net fixed asset turnover ratio suggests that the growth in property, plant, and equipment, net of accumulated depreciation, outpaced sales growth. This could be attributed to strategic investments in capacity expansion, modernization, or acquisitions, which initially require capital expenditure before generating increased revenue.

The consistent decrease in the net fixed asset turnover ratio warrants further investigation to determine the underlying causes and assess the long-term implications for asset utilization and profitability. A deeper analysis should consider the specific investments made in fixed assets and their corresponding impact on sales generation.


Total Asset Turnover

Danaher Corp., total asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Sales
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Total asset turnover = (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The total asset turnover ratio for the analyzed period demonstrates a generally declining trend, with some quarterly fluctuations. Initially, the ratio exhibited a slight increase before entering a period of consistent decrease. Recent quarters suggest a potential stabilization, though at a lower level than observed earlier in the period.

Initial Trend (Apr 1, 2022 – Sep 30, 2022)
The ratio began at 0.36 and increased to 0.39 over the first four quarters. This indicates improving efficiency in asset utilization during this timeframe, suggesting the company was generating more sales revenue per dollar of assets.
Declining Trend (Dec 31, 2022 – Jun 30, 2023)
Following the initial increase, the ratio experienced a consistent decline from 0.37 to 0.33. This suggests a decreasing efficiency in asset utilization, potentially due to slower sales growth relative to the asset base, or an increase in assets without a corresponding increase in sales.
Stabilization and Recent Performance (Sep 29, 2023 – Jun 27, 2025)
From September 2023 through June 2025, the ratio fluctuated between 0.28 and 0.30, indicating a period of relative stabilization. The most recent value, 0.29, suggests that asset utilization has remained relatively consistent, but at a lower level than previously observed. While not exhibiting further decline, a return to the levels seen in the first half of 2022 has not materialized.

The overall trend suggests a potential shift in the company’s operational efficiency regarding asset utilization. Further investigation into the underlying drivers of these changes, such as sales growth, asset composition, and industry benchmarks, would be necessary to provide a more comprehensive assessment.

Highest and Lowest Values
The highest recorded ratio was 0.39, observed on September 30, 2022. The lowest recorded ratio was 0.28, observed on both December 31, 2022 and September 29, 2023.

The observed fluctuations warrant continued monitoring to determine if the recent stabilization represents a new normal or a temporary pause in the declining trend.


Equity Turnover

Danaher Corp., equity turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Sales
Total Danaher stockholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Equity turnover = (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025) ÷ Total Danaher stockholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The equity turnover ratio for the analyzed period demonstrates a generally declining trend, with some fluctuations. Initially, the ratio exhibited relative stability before experiencing a more pronounced decrease in later periods. This suggests a changing relationship between sales and stockholders’ equity over time.

Overall Trend
The equity turnover ratio began at 0.65 in April 2022 and generally decreased to 0.47 by December 2025. While there were minor increases within the timeframe, the overall direction is downward. This indicates that the company is generating less sales revenue for each dollar of equity invested.
Initial Stability & Early Decline (Apr 2022 – Dec 2022)
From April 2022 to December 2022, the ratio fluctuated between 0.65 and 0.67, indicating a period of relative stability. A slight decrease to 0.63 was observed in December 2022, signaling the beginning of a downward trend.
Accelerated Decline (Mar 2023 – Sep 2023)
The period from March 2023 to September 2023 witnessed a more significant decline, moving from 0.58 to 0.49. This suggests a potential shift in operational efficiency or a change in the capital structure impacting sales generation.
Recent Fluctuations & Stabilization (Dec 2023 – Dec 2025)
From December 2023 to December 2025, the ratio experienced further fluctuations, ranging from 0.45 to 0.47. While there isn’t a clear upward or downward trajectory in this recent period, the ratio remains at the lower end of the observed range, indicating continued lower sales generation relative to equity.

The consistent decline in equity turnover warrants further investigation. Potential contributing factors could include increased equity levels without a corresponding increase in sales, decreased asset utilization efficiency, or changes in the company’s business strategy. A deeper analysis of the underlying components of both sales and equity is recommended to understand the drivers behind this trend.